# Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT00677079** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 12 (actual)

## Conditions studied

- Primary Peritoneal Cancer
- Advanced Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Iniparib

## Key facts

- **NCT ID:** NCT00677079
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677079, "Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00677079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*